| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/21/2023 | 1197.71% | Cantor Fitzgerald | → $17 | Reiterates | Overweight → Overweight |
| 08/31/2023 | — | Jefferies | Upgrades | Hold → Buy | |
| 08/31/2023 | 1197.71% | Cantor Fitzgerald | $23 → $17 | Maintains | Overweight |
| 08/07/2023 | — | Maxim Group | Downgrades | Buy → Hold | |
| 08/04/2023 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 08/04/2023 | 52.67% | Piper Sandler | $7 → $2 | Downgrades | Overweight → Neutral |
| 08/04/2023 | 14.5% | Chardan Capital | $2 → $1.5 | Maintains | Sell |
| 05/30/2023 | 52.67% | Chardan Capital | $2.5 → $2 | Maintains | Sell |
| 03/01/2023 | 90.84% | Chardan Capital | → $2.5 | Reiterates | → Sell |
| 02/01/2023 | 1655.73% | Cantor Fitzgerald | → $23 | Reiterates | → Overweight |
| 12/06/2022 | — | Jefferies | Downgrades | Buy → Hold | |
| 09/06/2022 | 434.35% | Piper Sandler | → $7 | Initiates Coverage On | → Overweight |
| 06/03/2022 | 90.84% | Chardan Capital | $6.5 → $2.5 | Maintains | Sell |
| 08/31/2021 | 396.18% | Chardan Capital | $7.5 → $6.5 | Maintains | Sell |
| 04/07/2021 | — | Maxim Group | Upgrades | Hold → Buy | |
| 01/19/2021 | — | Jefferies | Downgrades | Buy → Hold | |
| 12/22/2020 | — | Maxim Group | Downgrades | Buy → Hold | |
| 12/04/2020 | 472.52% | Chardan Capital | $5.5 → $7.5 | Downgrades | Neutral → Sell |
| 11/20/2020 | 1426.72% | HC Wainwright & Co. | $19 → $20 | Maintains | Buy |
| 10/22/2020 | 816.03% | RBC Capital | → $12 | Initiates Coverage On | → Sector Perform |
| 10/02/2020 | 1350.38% | HC Wainwright & Co. | $21 → $19 | Maintains | Buy |
| 05/28/2020 | 1503.05% | HC Wainwright & Co. | $14 → $21 | Reiterates | → Buy |
| 10/22/2019 | 1655.73% | Cantor Fitzgerald | → $23 | Assumes | → Overweight |
| 01/31/2019 | 396.18% | HC Wainwright & Co. | → $6.5 | Assumes | → Buy |
What is the target price for Mesoblast (MESO)?
The latest price target for Mesoblast (NASDAQ: MESO) was reported by Cantor Fitzgerald on September 21, 2023. The analyst firm set a price target for $17.00 expecting MESO to rise to within 12 months (a possible 1197.71% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Mesoblast (MESO)?
The latest analyst rating for Mesoblast (NASDAQ: MESO) was provided by Cantor Fitzgerald, and Mesoblast reiterated their overweight rating.
When is the next analyst rating going to be posted or updated for Mesoblast (MESO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mesoblast, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mesoblast was filed on September 21, 2023 so you should expect the next rating to be made available sometime around September 21, 2024.
Is the Analyst Rating Mesoblast (MESO) correct?
While ratings are subjective and will change, the latest Mesoblast (MESO) rating was a reiterated with a price target of $0.00 to $17.00. The current price Mesoblast (MESO) is trading at is $1.31, which is within the analyst's predicted range.